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Background: Borrelia burgdorferi, the causative agent of Lyme disease (LD), and Babesia, 
Bartonella, and Ehrlichia species (spp.) are recognized tick-borne pathogens in humans 
worldwide. Using serology and molecular testing, the incidence of these pathogens was 
investigated in symptomatic patients from Australia.
Methods: Sera were analyzed by an immunofluorescent antibody assay (IFA) followed by 
immunoglobulin (Ig)G and IgM Western blot (WB) assays. Both whole blood and sera were 
analyzed for detection of specific Borrelia spp. DNA using multiplex polymerase chain reac-
tion (PCR) testing. Simultaneously, patients were tested for Babesia microti, Babesia duncani, 
Anaplasma phagocytophilum, Ehrlichia chaffeensis, and Bartonella henselae infection by IgG 
and IgM IFA serology, PCR, and fluorescent in situ hybridization (FISH).
Results: Most patients reported symptom onset in Australia without recent overseas travel. 28 
of 51 (55%) tested positive for LD. Of 41 patients tested for tick-borne coinfections, 13 (32%) 
were positive for Babesia spp. and nine (22%) were positive for Bartonella spp. Twenty-five 
patients were tested for Ehrlichia spp. and (16%) were positive for Anaplasma phagocytophilum 
while none were positive for Ehrlichia chaffeensis. Among the 51 patients tested for LD, 21 
(41%) had evidence of more than one tick-borne infection. Positive tests for LD, Babesia 
duncani, Babesia microti, and Bartonella henselae were demonstrated in an individual who 
had never left the state of Queensland. Positive testing for these pathogens was found in three 
others whose movements were restricted to the east coast of Australia.
Conclusion: The study identified a much larger tick-borne disease (TBD) burden within the 
Australian community than hitherto reported. In particular, the first cases of endemic human 
Babesia and Bartonella disease in Australia with coexisting Borrelia infection are described, 
thus defining current hidden and unrecognized components of TBD and demonstrating local 
acquisition in patients who have never been abroad.
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Introduction
Human tick-borne disease (TBD) is an increasing health burden on the Australian commu-
nity requiring wider diagnostic recognition. TBD comprises multiple specific zoonoses, 
some of which are well recognized and documented, including tick paralysis and rick-
ettsial disease as reported at a Sydney University Website (Entomology).1 The present 
study addresses recent evidence for emerging Borrelia, Babesia, Bartonella,   Anaplasma, 
and Ehrlichia infections in Australia. The study confirms previously published work 
on the existence of human Borrelia infection in Australia.2,3 There are no further pub-
lications on human Lyme disease (LD) in the interval using a search on PubMed on 
October 3, 2011 for the MeSH headings of humans, Borrelia, and Australia. The study 
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also examines the incidence of tick-borne coinfections, some 
of which occur in patients who have never left Australia.
The country has 75 tick species1 with general acceptance 
of Ixodes spp. and Ixodes holocyclus (Ih) in particular, as the 
main contenders in inducing human TBD in the country.4,5 
The entire eastern coastline is habitat to Ih and it is known to 
vector human disease including rickettsial infection and tick 
paralysis.1,4,6,7 The Ih tick is colloquially named paralysis 
tick, grass tick, shell back tick, and several other names.1 It 
thrives in humid conditions along the coast, mainly in flat-
lands, from the north of the continent just above Cooktown 
in Queensland to Lake Entrance in Victoria at the very south 
of the continent. The region has a very high proportion of 
Australia’s human population.
The Ih tick has a larval, nymph, and adult form all of 
which require a blood meal.1 Larvae typically feed upon 
small animal hosts whilst nymph and adult will include larger 
  animals. Humans are incidental hosts to the latter two forms. 
The tick may stay attached for up to 5–6 days before detach-
ing if not found. Many tick bites are not observed or reported.1 
Probably many of the nymph type, about the size of a pop-
pyseed, are simply scratched off particularly if attached to the 
scalp. In Australia a majority of bites will come to nothing 
more than a non-elevated erythematous macule on the skin 
of up to 2 cm diameter resolving completely over a few days 
providing the tick is removed promptly. Some lesions grow 
at the bite site to form a 2–3 cm papule by the second day 
showing a black central eschar.8 Such a presentation is the 
typical appearance of Queensland Tick Typhus, a rickettsial 
infection, at the bite sight and untreated this is followed by a 
“spotted rash” of widespread distribution known as rickettsial 
spotted fever, a febrile illness whose erythematous macules 
are typically 4–5 mm in diameter.6,7
Erythema Migrans (EM) is a local skin reaction to a 
tick bite caused by Borrelia burgdorferi sensu lato (Bb s.l.) 
infection.9,10 At this stage of infection the term Early Lyme 
Disease is also used and this terminology includes early 
systemic manifestations such as meningitis or cranial nerve 
neuropathy. After an initial 1-cm macular erythematous 
lesion, at day 2–5 or even later, the lesion will commence to 
grow in diameter and thicken for anywhere up to 14 days if 
left untreated. In Australia, the lesion will often become itchy 
and painful and rarely there will be central induration and 
paling of color which gives the bull’s eye classically referred 
to in LD literature. This has been the author’s observation 
over 20 years in his current practice in Australia. A single 
primary lesion must reach more than 5 cm in size to be classi-
fied as an EM and then it is considered to be pathognomonic.11 
When documented in a known tick area it is also considered 
sufficient for a clinical diagnosis of LD.
LD is a protean multisystem illness that develops 6 months 
to 8 years after a tick bite that carries the borrelia spirochaete.12 
Nomenclature of the stages of the disease includes the use of 
the terminology early disseminated LD and late disseminated 
disease.13 In North America a principal symptom of the disease 
is an arthritic illness that may have severe pain and swelling, 
more of large joints, and can be associated with marked general 
fatigue and other somatic features.13 The US Centers for 
Disease Control and Prevention (CDC) website further states 
that in the musculoskeletal system, LD produces recurrent 
attacks of arthritis with objective joint swelling in one or a few 
joints, sometimes followed by chronic arthritis.13 LD in North 
America may also be principally a neurological disease which 
is generally accepted to be the case throughout Europe and 
Asia. In the case load presented here it is entirely a neurological 
disease with symptoms of meningism, cranial neuropathy, and 
sometimes encephalopathy. Of importance is the large number 
of cranial nerves involved including sensory. Such a factor 
precludes diagnoses of multiple sclerosis, motor neuron disease, 
amyotrophic lateral sclerosis, chronic fatigue, fibromyalgia, and 
several others in the author’s opinion, leaving only sarcoid, 
bartonellosis, borreliosis, and the autoimmune neurological 
diseases (one of which is commonly known to every medical 
graduate as Guillain–Barré syndrome) as differential diagnoses. 
The latter residual differential diagnosis is put forward by the 
author after discussion with neurological colleagues.
Treatment of EM and early localized disease is usually 
very effective. Treatment of the later disseminated stage of 
the disease will usually be straight forward when identified 
early. Other cases can be protracted and treatment much more 
difficult. In this latter group there can be immune suppres-
sion known to be an innate response to the Lyme bacterium. 
Stricker and Winger first identified immune dysfunction 
demonstrated by lowered CD57 natural killer cell counts 
associated with LD.14
Babesia spp. are piroplasms that invade red blood cells.15 
In the developing world babesiosis is frequently mistaken for 
malaria which it symptomatically mimics in the acute phase. 
Most healthy individuals recover completely from infection 
with this piroplasm over 4 or more weeks. A very few go 
on to chronic infection. The disease can be fatal in the acute 
stage with multiorgan failure due to intravascular hemolysis 
and stasis, particularly in splenectomised individuals. There 
is a large emerging incidence of low-grade babesiosis in 
association with LD in North America. Treatment for babe-
siosis in the presence of Lyme borreliosis is very difficult. 
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Drug therapy is similar to that for malaria. Clinical symptoms 
and signs as a TBD are intermingled with those of LD, are 
complex, and beyond the scope of this work.
Bartonella henselae is a Gram-negative intracellular 
bacterium.16 Alone it has been known to be the cause of 
cat scratch fever particularly in pediatric medicine where 
it is defined by its hallmark of pink striae that are quite 
unmistakable. The infection causes an acute febrile illness 
in solitary infection. However it can also be tick-borne, and 
whilst attention is given to EM and LD, it can be overlooked, 
just as Babesia is in the acute phase. Bartonellosis may go 
on to cause chronic symptoms identical to or confounding 
those of neuroborreliosis. Also it is extremely important in all 
documented cases to consider thorough cardiac assessment 
for both endocardial and myocardial damage. CDC gives a 
good overview.17
Human granulocytic ehrlichosis (HGE) alternatively known 
as human granulocytic anaplasmosis is an infection of the neu-
trophil line of white blood cells.16,18 The agent is a rickettsia. 
Onset of symptoms can be as bland as a febrile illness after 
exposure by typically 4 weeks. HGE can present much more 
seriously and can be fatal. The only significant routine labora-
tory finding is a low white blood cell count. The infection will 
only be confirmed by suspicion and   further serological testing. 
Treatment should commence whilst waiting for serology.
Human monocytic ehrlichosis (HME) like HGE, is an 
infection caused by a rickettsial spp. but of the monocyte 
rather than of the neutrophil cell line.18,19 Though reported in 
North America, HME was not found in this study.
Materials and methods
The author is a general practitioner with specific interest and 
training in dermatology and LD. Most of the patients in the 
series were self-referred having found the author’s interest in 
LD. Some were referred from the University of Newcastle, 
and some from other doctors. The demographic spread of these 
patients involved the entire eastern seaboard of   Australia for 
either residency or holidaying. Many had travelled overseas and 
walked or hiked in nature through Asia, Europe, or Northern 
America. While only some had a clear memory of tick bites, 
and even fewer any recollection of a rash the size of EM, most 
were unable to pinpoint where they could have been exposed, 
among several   possible countries and outdoor exposure 
including Australia. Patients presented with a broad range of 
clinical symptoms consistent with multisystem disorder. The 
minimum length of illness was 8 months, while the maximum 
was 12 years. Investigation was recommended for all cases 
where LD was considered possible from a clinical perspective. 
All cases of potential tick-borne disease referred from 
November 2009 to August 2011 for serological and PCR 
testing of any description for the above diseases at IGeneX in 
Palo Alto, CA, were included in this survey. Three patients 
presented with these tests already done and are included. Two 
patients attended from New Zealand. At the same time others 
were tested by Australian laboratories. Testing for Babesia, 
Bartonella, and Ehrlichia spp. could be offered only by 
IGeneX, however. A total of 51 patients had testing at IGeneX 
over the 18 months of the survey. In the same period a smaller 
number had other tests in Australia for Bb enzyme-linked 
immunosorbent assay ELISA, all of which were negative, and 
a number underwent polymerase chain reaction (PCR) analysis 
for borrelia DNA, some of whom tested positive. A further 
subset of those positives had confirmation by sequencing. This 
non-IGeneX group is the subject of future research. Many had 
no testing of this type because of patient cost.
IGeneX is a major laboratory specializing in TBDs. It is 
a reference laboratory recognized by the American College 
of Pathologists, and is Clinical Laboratory Improvement 
Amendments, Medicare, and Medicaid approved thus 
  satisfying licensing requirements for most of the US states 
to perform high complexity clinical testing. IGeneX has also 
met licensing requirements in the states requiring additional 
licensing: California, Florida, Maryland, New York, and 
Pennsylvania. Statements concerning laboratory performance 
and validation in the area of quality assurance in LD testing 
are available on the IGeneX website.20
Blood was collected in EDTA tubes and serum   separator 
tubes, stood for 30 minutes, and then centrifuged before 
dispatch. A hemolyzed specimen was discarded. Sera were 
analyzed by an immunofluorescent antibody assay (IFA) 
followed by immunoglobulin (Ig)G and IgM Western blot 
(WB) assays. Both whole blood and sera were analyzed for 
detection of specific Borrelia spp. DNA using multiplex 
PCR testing. IGeneX multiplex B. burgdorferi PCR detects 
specific DNA sequences from Osp A plasmid and flagellin 
genomic genes. The test is not B. burgdorferi specific and also 
detects B. afzelii, B. andersoni, and B. garinii. Simultaneously 
patients were tested for Babesia microti, Babesia duncani, 
Anaplasma phagocytophilum, Ehrlichia chaffeensis, and 
Bartonella henselae infection by IgG and IgM IFA serology, 
PCR, and fluorescent in situ hybridization (FISH).
Results
Borrelia
Fifty-one patients were tested for Lyme Borreliosis and 
28 showed positive test results (Table 1). IFA (IgG/M/A) 
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serologic reactivity to Bb antigens was demonstrated in 
13 patients; one with a titer of 1:160, three with titers of 1:80 
and nine patients with titers of 1:40. WB banding patterns are 
provided on reports and are interpreted both by IgeneX stan-
dards and CDC surveillance standards, as discussed below. 
Patterns for IgM WB revealed three patients seroreactive to 
the 23–25 kDa protein, seven to the 31 kDa protein, four to the 
34 kDa protein, four to the 39 kDa protein, 28 to the 41 kDa 
protein, and three to the 83–93 kDa protein. Patterns for IgG 
WBs revealed three patients seroreactive to the 23–25 kDa 
protein, two at the 30 kDa protein, seven to the 31 kDa protein, 
three to the 34 kDa protein, five to the 39 kDa protein, 16 to the 
41 kDa protein, and zero to the 83–93 kDa protein (Table 1). 
PCR assays detected plasmid DNA in serum samples from 
eight patients and in whole blood samples from two patients 
(Table 1). Twenty-eight patients had positive WB by IGeneX 
standards (Table 1). Twenty patients had WBs that were 
positive to the strict CDC WB surveillance criteria (discussed 
below); six lacked sufficient IgG reactivity to be CDC-positive 
and a further two lacked IgM reactivity. Reactivity to the 
flagellin band 41 kDa was universal on all WB results but 
this is a common denominator across all spirochetes. A high 
incidence of reactivity to the 31 and 58 kDa proteins merits 
further evaluation. In a report from China in 2010, Jiang et al 
studied 127 Lyme borreliosis-positive patients (B. garinii 
strain PD91) and 504 negative controls and proposed that 
band 58 is important diagnostically in that country for their 
major strain of Borrelia infection.21 In this Australian study, 
14 out of 28 positives showed band 58 on either IgG or IgM. 
Band 58 may signify B. garinii in Australia.
IFA, WB, and PCR test results vary from patient to patient 
with no clear pattern emerging as to which technique is more 
likely to show evidence of LD. Isolated WB positivity (no 
IFA or PCR positivity) was found in 12 of the 28 cases. 
Only one case of isolated PCR positivity (IFA and WB 
negative) was found. Of most importance is the fact that 13 
patients with diagnostically positive WB and negative IFA 
would have been undiagnosed if IFA had been used as an 
Table 1 Borrelia burgdorferi positive laboratory test results
Patient Lyme  
IFA titer
IgM WB IgG WB PCR serum PCR blood
 1 Pos 31, 41, 83–93 Pos 18, 31, 39, 41, 45, 58, 66
 2 Plasmid
 3 40 23–25, 30 Pos 18, 34, 41, 58
 4 40 Pos/CDC 39, 41, 58 41, 45, 58
 5 80 66 Pos 31, 41, 58
 6 Pos 31, 41
 7 Pos 18, 23–25, 41, 58
 8 40 Pos/CDC 23–25, 31, 34, 39, 41, 58, 66, 83–93 41
  9 30, 41 Pos 31, 41, 58
10 Pos 18, 23–25, 28, 30, 31, 34, 41, 58
11 40 41, 58 Plasmid
12 Pos 31, 34, 41, 58, 66 41, 58
13 .80 Pos 31, 41
14 80 Pos 31, 34, 41 Plasmid
15 41, 58 Pos 18, 34, 41, 58
16 40 Pos 39, 41
17 Pos 31, 41 Pos 39, 41
18 Plasmid
19 80 pos 18, 34, 41, 58, 66 41
20 40 Pos/CDC 23–25, 41, 83–93 41, 58
21 Pos 23–25, 41
22 40 Pos 31, 41, 83–93 Plasmid
23 18, 83–93 Pos 39, 41, 58
24 40 Pos 31, 41 41, 56 Plasmid
25 Pos 23–25, 30, 41, 66 Plasmid
26 40 Pos/CDC 39, 41 Pos 39, 41 Plasmid
27 Pos/CDC 23–25, 39, 41 Pos 30, 31, 41
28 Pos 31, 41
n 9 at 1:40 13 Pos 15 pos 6 2
4 at 1:80 5 CDC Nil CDC
Notes: Pos, positive Western blot bands by Igenex standards; CDC, positive Western blot bands by CDC surveillance criteria: combined count showing kDa 58 protein is 14.
Abbreviations: IFA, immunofluorescent antibody assay; Ig, immunoglobulin; PCR, polymerase chain reaction; WB, Western blot.
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obligatory screening test prior to WB testing. See tabulation 
of results in Table 1.
Babesia
Forty-one patients were tested for babesiosis (both B. duncani 
and B. microti) and 13 tested positive (Table 2). Two of these 
patients had positive Babesia Fluorescent in situ   Hybridization 
(FISH) results. Two patients demonstrated positive IgM reac-
tivity for B. duncani, one with a 1:160 titer and one with a 
1:80 titer. Six patients demonstrated IgG reactivity, three 
with titers of 1:80 and three with titers of 1:40. B. Duncani 
DNA was detected by PCR in one patient. IgM seroreactivity 
was demonstrated in two patients, and a titer of 1:20 and IgG 
seroreactivity was demonstrated in four patients with a titer 
of 1:40. IFA was used to detect antibody/antigen reactivity. 
In no instance was serology done at acute onset.
Bartonella
Forty-one patients were tested for bartonellosis, nine of 
whom tested positive (Table 2). IFA was used to detect 
antibody/antigen reactivity. Two demonstrated positive 
IgM reactivity at a titer of 1:40 and two at a titer of 1:20. 
Four patients demonstrated IgG reactivity: one at titer of 
1:80 and three at a titer of 1:40. Bartonella PCR and FISH 
assays were performed but were negative in all cases. In no 
instance was serology done at acute onset. For these and also 
the babesiosis findings above, many months of symptoms 
had passed before all specimen collections. Positive results 
from any of the tests triggered clinical suspicion of disease 
and consideration of treatment for those identifiable clinical 
features that had triggered the investigation.
Human granulocytic ehrlichiosis (HGE) and human 
monocytic ehrlichiosis (HME)
Twenty-five patients were tested for HGE and HME. Of 
these, four were serologically positive. All these patients 
had travelled outside Australia, but one reported travel only 
to Fiji for 2 weeks and had documented multiple tick bites 
on 1 day in Australia. HME is an emerging TBD in North 
America but will not be discussed further in this document 
as the presence of Ehrlichia chaffenesis was not detected in 
laboratory tests of any of the 25 patients.
HGE positive IFA serological results were as follows: 
IgM, two patients at a titer 1:20, IgG, one patient at 1:80 
and one patient at 1:40. In no instance was serology done at 
acute onset. Many months of symptoms had passed before all 
specimen collections. Of note is the fact that all these patients 
had negative Australian Rickettsial studies.
Finally the 21 patients who demonstrated evidence of 
the studied coinfections formed a discrete subset of the 28 
Bb-positive laboratory test patients.
Patients who had never travelled outside Australia
A group of four patients reported having never travelled 
outside Australia. Their geographic movements within 
Australia portray a lifelong picture. See Table 3 for results 
summary.
Patient A is a child (number 27 in table 1) who travelled 
from Byron Bay NSW to Eastlakes Victoria by caravan but 
resided on the mid-north coast of NSW. This patient had 
Lyme IgM WB positive at bands 23–25, 39 and 41 KDa, 
while B. henselae serology for IgM was positive at a titer 
of 1:40.
Patient B is an adult (number 24 in Table 1) who 
has always lived in Queensland but has travelled to 
Northern NSW, Sydney, Melbourne, and Hobart. Yepoon 
  Queensland is the furthest north he has been. Lyme IFA 
was 1:40, Lyme WB IgM was positive at bands 31 and 
41 kDa, Borrelia PCR was positive for plasmid. B. duncani, 
IgG serology was positive at 1:40, B. microti IgG serology 
was positive at 1:40 and B. henselae IgM serology was 
positive at 1:40.
Patient C is an adult (number 19 in Table 1) who has 
lived in Queensland, except Karratha Western Australia 
from age 2–7 and used to holiday repeatedly at Armstrong 
Beach Queensland which is the site of a cluster of LD already 














B. duncani 1 1 2 3 3 1
B. microti 1 2 4
Babesia FISH 2
B. henselae 2 2 1 3
Bartonella FISH Nil
Notes: 41 patients tested for both Babesia and Bartonella; discrete patient positives were Babesia 13 and Bartonella 9.
Abbreviations: FISH, fluorescent in situ hybridization; IFA, immunofluorescent antibody assay; Ig, immunoglobulin.
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identified by the author. Lyme IFA was 1:80, WB IgM was 
positive at 34 and 41 kDa, and Bartonella IgG serology was 
positive at 1:40.
Patient D is an adult (number 6 in Table 1) who was 
born in Victoria and then moved to NSW, from where he 
had travelled to Queensland as far north as Airlie Beach. He 
travelled into South Australia for 1 day once. Lyme WB was 
positive at 31 and 41 kDa and B. duncani was IgG positive 
1:40 titer.
Discussion
There has been considerable debate about the existence of 
LD in Australia. Published reports of both EM and locally 
acquired and proven human Borrelia burgdorferi infection in 
Australia are limited.2,3 At the time of the McCrossin study2 in 
1986 only serological diagnostic tests were available. For the 
Hudson study3 in 1998 Borrelia were cultured and identified 
with PCR in one patient with the results suggesting the bac-
teria were similar to European B. garinii in derivation rather 
than Asiatic spp. That person had previously been overseas. 
In the current setting we need first to examine the reporting 
of WB. By IGeneX standards the IgM or IgG WB is positive 
if two or more of the bands 23–25, 31, 34, 39, 41, 83–93, are 
present. For CDC surveillance criteria for IgM, two or more 
of the bands 23–25, 39, and 41 must be positive, while the 
CDC IgG surveillance criteria for WB is positive if five of 
the following bands are present: 18, 23–25, 28, 30, 39, 41, 
45, 58, 66, 83–93. Importantly it must be noted that the CDC 
has just amended its statement of criteria to include clinical 
impression. According to the website revised in   January 
2011: “Surveillance case definitions establish uniform cri-
teria for disease reporting and should not be used as the sole 
criteria for establishing clinical diagnoses, determining the 
standard of care necessary for a particular patient, setting 
guidelines for quality assurance, or providing standards for 
reimbursement.”22 These criteria were developed for report-
ing purposes (case definition).23 They were never meant to 
encompass the entire possible spectrum of LD and it is a 
scientific error to exclude a diagnosis of LD clinically when 
there are less than five bands on IgG WB as has been occur-
ring at Australian laboratories.
Lyme serological testing methods (ELISA, IFA, and 
WBs) although specific, lack sensitivity. Differences in WB 
performance and interpretation account for some of the varia-
tion in specificity and sensitivity reported among laboratories. 
PCR has become a gold standard of proof of infection, not 
just for LD, but all infections. A positive culture remains 
the absolute proof of infection, but a negative culture does 
not rule it out.
In this series, 51 patients were tested for the presence of 
Bb DNA with 8 patients demonstrating positive results for 
Borrelia multiplex PCR assays for plasmid DNA. One of 
these, patient B above, demonstrated positive PCR test results 
from a serum sample, yet had never left Australia. Patient B’s 
Lyme IFA was titered at 1:40, while the IgM WB showed 
positive bands at 31 and 41 kDa. In the author’s opinion this 
is the first published evidence of Bb infection verified by PCR 
where the infection was acquired within Australia. Of note is 
the fact that the infection progressed over a period of 3 years 
and the patient manifested the full classic triad of associated 
tick-borne diseases as discussed further below.
No cases of human babesiosis have been documented, 
either from B. duncani or B. microti in Australia. This study 
provides serological and DNA evidence that babesiosis 
exists in Australia, as demonstrated by the positive findings 
for IgG and IgM reactivity, FISH and PCR in 14 individuals 
tested out of 41 in Table 2. Among those who had never left 
  Australia, 2 patients, B and D, manifested weak serological 
evidence of babesiosis with negative PCR and FISH indi-
cating local acquisition of both B. microti and B. duncani 
coexisting with LD, and possible transmission by ticks.
B. henselae infection has been considered rare in 
  Australia. This study provides evidence that it should be 
considered as a TBD co-infection at any age as indicated 
by nine of the 41 patients (seven adults and two children) 
manifesting positive serology, though to date PCR and FISH 
Table 3 Positive laboratory test results of patients who have not left Australia






B. duncani B. Microti Bartonella
A 23–25, 39, 41 30, 31, 41 IgM titer 1: 40
B Titer 1:40 31, 41 To plasmid IgG titer 1:40 IgG titer 1:40 IgM titer 1: 40
C Titer 1:80 31, 42 IgM titer 1: 40
D 31, 41 IgG titer 1:40
Abbreviations: IFA, immunofluorescent antibody assay; Ig, immunoglobulin; PCR, polymerase chain reaction; WB, Western blot.
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have been negative (see Table 1). Furthermore patients A 
and C, who have never left Australia, provide evidence of 
local acquisition of B. henselae coexisting with LD and pos-
sible transmission by ticks.
Although there is currently no evidence of locally 
acquired ehrlichiosis it is evident from the study that in 
travellers and immigrants it could be brought into the coun-
try from overseas, and that the two tick-borne forms of the 
disease, HGE and HME, need to be considered in diagnostic 
evaluation.
All the above diseases are reported as emerging 
  infectious diseases worldwide, particularly in North 
America. This study shows Australia is no exception to the 
pattern. The broader topic warrants wider research than is 
presented here.
Conclusion
These results show a burden of TBD in Australia, which 
requires not only further research and evaluation but also 
a management response from the medical profession and 
Public Health entities of the eastern states. The long running 
discussion about the existence of LD in Australia needs to 
be put in a new perspective. This study demonstrates that 
it is endemic in Australia as is also babesiosis. Regardless 
of whether LD is acquired locally in Australia or acquired 
from abroad, the fact remains that Australian citizens are 
living in this country afflicted with this disease and are in 
need of treatment.
LD is protean in its manifestation and difficult to treat if 
protracted. The medical profession of Australia needs now 
to be alert to the possibility of detecting this disease early 
and in anyone with protracted illness who has neurologic 
symptoms particularly of the cranial nerves. The possibility 
of LD coinfection also needs to be examined in all cases 
given the findings here of 21 patients with a coinfection out 
of the 51 tested. Some patients were not tested for coinfection 
(cost consideration), and the incidence of these coinfecting 
pathogens could be higher. Australia currently lacks facilities 
to investigate all aspects of LD, a matter which needs to be 
redressed, and testing funded appropriately for Australians 
as a health priority. State Public Health Authorities in all 
states of the Commonwealth need to develop an adequate 
program for detection, monitoring and treatment of the TBDs 
discussed here as a matter of urgency. Public health education 
programs need to be put in place in an effort to reduce the 
current disease burden regardless of whether its acquisition 
is local or foreign.
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